The deletion of CNPY2 has been shown to block the PERK–CHOP pathway, and this protected against NAFLD induced in animal models by HFD or with tunicamycin [47]. The gene discussed is EIF2AK3; the disease is metabolic dysfunction-associated steatotic liver disease.